Vycor Issued Hong Kong Patent for Its VBAS Minimally Invasive Brain Access System
2013年3月25日 - 9:30PM
Marketwired
Vycor Medical, Inc. ("Vycor") (OTCBB: VYCO), a provider of
innovative and superior surgical and therapeutic solutions,
announced it has been issued patent number 10106385.8 for its
ViewSite™ Brain Access System ("VBAS") for the Hong Kong market.
Vycor has a distribution agreement in place with Devon Medical
which covers Hong Kong and China.
The addition of this patent brings the Vycor's total patent
portfolio to 32 issued and 23 pending. Management views its
significant patent portfolio to be of strategic importance and
believes it will help drive future revenue and underpins the
Company's valuation.
VBAS is a suite of clear cylindrical disposable devices which
provide neurosurgeons a stable, minimally invasive working channel
to access targeted sites within the brain, such as tumors. The
"blade retractor" has been the standard of care device for brain
access and retraction with little change for more than 50 years.
VBAS is now approved in over 100 hospitals in the U.S. and the
number continues to grow. To date, more than 4,000 surgeries have
been performed utilizing VBAS.
The Company is targeting international markets of size where it
has patent protection and has or is in the process of obtaining
regulatory approvals. In Europe, Vycor's growth focus will be on
the UK, France, Germany, Austria and Switzerland. Elsewhere, the
focus will be on Japan and Russia, where it already has regulatory
approvals. The Company also plans to enter the large Indian market
and is currently in discussions with various distributors.
VBAS is ISO 13485:2003 compliant, has U.S. FDA 510(k) Clearance
for brain and spine surgeries, and regulatory approvals for brain
surgeries in Australia, Canada, China, Europe, Japan, Korea and
Russia.
David Cantor, Vycor's President, stated, "The addition of the
Hong Kong patent builds upon our significant IP portfolio
surrounding our VBAS device. Outside the U.S., there are
approximately 800,000 neurosurgical procedures annually which can
be addressed by our existing VBAS product line which equates to a
market potential of approximately $285 million. We currently have
distribution agreements in place for VBAS in Australia, China,
Germany, Greece, Holland, Hong Kong, Italy, Japan, Korea, Spain,
Sweden and the UK. We expect to be entering into a number of
additional international distribution agreements this year."
About Vycor Medical, Inc. With corporate
headquarters in Boca Raton, FL, Vycor Medical, Inc. ("Vycor") is a
publicly traded company (OTCBB: VYCO) dedicated to providing the
medical community with innovative and superior surgical and
therapeutic solutions and has a growing portfolio of FDA-approved
medical solutions that are changing and improving lives every day.
The Company operates two business units: Vycor Medical and
NovaVision, both of which adopt a minimally or non-invasive
approach. Both technologies have exceptional sales growth
potential, address large potential markets, have the requisite
regulatory approvals and are commercialized and generating revenue.
The Company has a strong patent portfolio with 32 granted patents
and a further 23 patents pending.
Vycor Medical's flagship, ViewSite™ Surgical Access Systems
(VBAS) is a suite of clear cylindrical minimally invasive
disposable devices that hold the potential for speedier, safer and
more economical brain surgeries and a quicker patient discharge.
VBAS is designed to optimize neurosurgical site access, reduce
patient risk, accelerate recovery and add tangible value to the
professional medical community. Vycor Medical is ISO 13485:2003
compliant, has FDA 510(K) clearance for VBAS for brain and spine
surgeries and regulatory approvals for brain surgeries in
Australia, Canada, China, Europe, Japan, Korea and Russia. For an
overview of Vycor Medical's VBAS see
http://player.vimeo.com/video/39766887
NovaVision develops and provides science-driven neurostimulation
therapy and other medical technologies that help improve and
partially restore sight in patients with neurological vision
impairments. The company's proprietary Visual Restoration Therapy®
(VRT) platform is clinically supported to improve lost vision
resulting from stroke, traumatic brain injury ("TBI"), or other
acquired brain injuries. VRT is the only FDA 510K cleared medical
device in the U.S. aimed at the restoration of vision for
neurologically induced vision loss and can be prescribed by any
ophthalmologist, optometrist, neurologist or physiatrist. VRT also
has CE Marking for the EU. NovaVision also provides Neuro-Eye
Therapy (NeET) in the EU, aimed at increasing visual sensitivity
deep within the field defect. NovaVision also provides a fully
portable and ADA-compliant Head Mounted Perimeter (HMP™) which aids
in the detection and measurement of visual field deficits. For an
overview of NovaVision see
http://player.vimeo.com/video/39765566
For the latest information on the company, including media and
other coverage, and to learn more, please go online at
www.vycormedical.com or www.novavision.com.
Safe Harbor Statement
Information in this document constitute
forward-looking statements or statements which may be deemed or
construed to be forward-looking statements within the meaning of
the Private Securities Litigation Reform Act of 1995. The words
"forecast", "anticipate", "estimate", "project", "intend",
"expect", "should", "believe", and similar expressions are intended
to identify forward-looking statements. These forward-looking
statements involve, and are subject to known and unknown risks,
uncertainties and other factors which could cause Vycor Medical's
actual results, performance (financial or operating) or
achievements to differ from the future results, performance
(financial or operating) or achievements expressed or implied by
such forward-looking statements. The risks, uncertainties and other
factors are more fully discussed in Vycor Medical's filings with
the U.S. Securities and Exchange Commission. All forward-looking
statements attributable to Vycor Medical herein are expressly
qualified in their entirety by the above-mentioned cautionary
statement. Vycor Medical disclaims any obligation to update
forward-looking statements contained in this estimate, except as
may be required by law.
Vycor Medical, Inc. Investor Contacts: The Del Mar
Consulting Group, Inc. Robert B. Prag President 858-794-9500 Email
Contact or Alex Partners, LLC Scott Wilfong President 425- 242-0891
Email Contact
Vycor Medical (QB) (USOTC:VYCO)
過去 株価チャート
から 6 2024 まで 7 2024
Vycor Medical (QB) (USOTC:VYCO)
過去 株価チャート
から 7 2023 まで 7 2024